Cargando…
Pegaptanib in the treatment of wet, age-related macular degeneration
Age-related macular degeneration (AMD) is a major cause of severe visual loss worldwide. Neovascular (wet) AMD accounts for 90% of the visual loss associated with the disorder and vascular endothelial growth factor (VEGF) has been shown to play a major role in neovascularization and vascular permeab...
Autor principal: | Vinores, Stanley A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2426796/ https://www.ncbi.nlm.nih.gov/pubmed/17717967 |
Ejemplares similares
-
Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration
por: Sivaprasad, Sobha
Publicado: (2008) -
Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK
por: Sivaprasad, Sobha, et al.
Publicado: (2008) -
Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany
por: Feucht, Nikolaus, et al.
Publicado: (2008) -
Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study
por: Friberg, Thomas R, et al.
Publicado: (2010) -
Effect of Switching Therapy to Pegaptanib in Eyes With the Persistent Cases of Exudative Age-Related Macular Degeneration
por: Shiragami, Chieko, et al.
Publicado: (2014)